Article
Oncology
Kazuko Sakai, Takayuki Takahama, Mototsugu Shimokawa, Koichi Azuma, Masayuki Takeda, Terufumi Kato, Haruko Daga, Isamu Okamoto, Hiroaki Akamatsu, Shunsuke Teraoka, Akira Ono, Tatsuo Ohira, Toshihide Yokoyama, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Kazuto Nishio
Summary: The WJOG8815L phase II clinical study examined the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA from NSCLC patients receiving osimertinib treatment. Results showed a decrease in sensitizing and T790M-EGFR mutant fractions during treatment, with a rebound of sensitizing EGFR MF observed at disease progression or treatment discontinuation. Significant differences in response rates and progression-free survival were observed based on sensitizing EGFR MF grouping at cycle 4.
MOLECULAR ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Eiji Oki, Takayuki Yoshino
Summary: The ongoing CIRCULATE-Japan trial is investigating the role of ctDNA-based molecular residual disease testing in patients with resectable colorectal cancer after surgery. An interim analysis of GALAXY, a prospective observational arm, confirms ctDNA as a prognostic and predictive biomarker.
Article
Biochemical Research Methods
Jace Webster, Ha X. Dang, Pradeep S. Chauhan, Wenjia Feng, Alex Shiang, Peter K. Harris, Russell K. Pachynski, Aadel A. Chaudhuri, Christopher A. Maher
Summary: The detection of genomic alterations in ctDNA is important for clinical monitoring of cancer. However, strategies for detecting SVs in ctDNA are limited, and the analysis of different classes of variants is challenging. We developed a unified pipeline called PACT for accurate and consistent analysis of ctDNA, which outperformed similar tools in various datasets.
Article
Oncology
E. E. Dumbrava, S. G. Call, H. J. Huang, A. L. Stuckett, K. Madwani, A. Adat, D. S. Hong, S. A. Piha-Paul, V. Subbiah, D. D. Karp, S. Fu, A. Naing, A. M. Tsimberidou, S. L. Moulder, K. H. Koenig, C. H. Barcenas, B. K. Kee, D. R. Fogelman, E. S. Kopetz, F. Meric-Bernstam, F. Janku
Summary: Analysis of PIK3CA mutations in circulating tumor DNA is consistent with testing of archival tumor tissue. Low quantity of PIK3CA-mutant ctDNA is associated with longer survival, while a decrease in PIK3CA-mutant ctDNA during therapy is associated with longer time to treatment failure.
Article
Oncology
Irene Jimenez, Eleonore Frouin, Mathieu Chicard, Catherine Dehainault, Jessica Le Gall, Camille Benoist, Arnaud Gauthier, Eve Lapouble, Claude Houdayer, Francois Radvanyi, Virginie Bernard, Herve J. Brisse, Marion Gauthier-Villars, Dominique Stoppa-Lyonnet, Sylvain Baulande, Nathalie Cassoux, Livia Lumbroso, Alexandre Matet, Isabelle Aerts, Victor Renault, Francois Doz, Lisa Golmard, Olivier Delattre, Gudrun Schleiermacher
Summary: The analysis of circulating tumor DNA from non-hereditary retinoblastoma patients showed promising results in detecting ctDNA in plasma, despite challenges such as small tumor size and limited plasma sample volumes. This method may be beneficial for diagnosis, genetic counseling, and monitoring of residual intraocular disease.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Chemistry, Analytical
Yi-Hui Wang, Zhen Song, Xin-Yuan Hu, Huai-Song Wang
Summary: Tumor, an abnormal organism generated by cell proliferation and differentiation under various factors, involves gene mutations during tumorigenesis for diagnosis. Early diagnosis is crucial to improve cure rates and reduce mortality.
Article
Oncology
Brice Pastor, Thierry Andre, Julie Henriques, Isabelle Trouilloud, Christophe Tournigand, Marine Jary, Thibault Mazard, Christophe Louvet, Simon Azan, Audrey Bauer, Benoit Roch, Cynthia Sanchez, Dewi Vernerey, Alain R. Thierry, Antoine Adenis
Summary: This study demonstrates that pretreatment levels of cfDNA and mutant ctDNA may identify mCRC patients who could benefit from regorafenib treatment.
MOLECULAR ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Yanwei Song, Zheng Deng, Haoran Sun, Yucui Zhao, Ruyi Zhao, Jin Cheng, Qian Huang
Summary: Radiation resistant cells play a crucial role in tumor repopulation after radiotherapy, leading to treatment failure. Identifying the mechanism of these cells is vital for improving prognosis in cancer patients.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Chemistry, Multidisciplinary
Yunchao Xiao, Yu Fan, Wenzhi Tu, Yuesheng Ning, Meifang Zhu, Yong Liu, Xiangyang Shi
Summary: Simultaneous inhibition of primary tumors and tumor metastasis was achieved using a unique platform based on DNA aptamer-functionalized microfibrous rings. The multifunctional fibrous rings displayed good biocompatibility, pH-dependent drug release, and high r(1) relaxivity.
Article
Biochemistry & Molecular Biology
Bangquan Liu, Jiabao Zhai, Wanyu Wang, Tianyu Liu, Chang Liu, Xiaojie Zhu, Qi Wang, Wenjing Tian, Fubin Zhang
Summary: The tumor microenvironment and DNA methylation-related prognostic signature can accurately predict the prognosis of cervical cancer and may be important for stratified management of patients and precision targeted therapy. High immunity levels in CC patients are associated with better survival outcomes.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Otorhinolaryngology
Kaixuan Yang, Mei Li, Jinbing Zhu, Lei Zeng, Jiangfang Tian, Wenji Xie, Arthur Shou, Yiping Li, Guangjun Li
Summary: The study confirmed the successful prediction of survival outcomes for nasopharyngeal carcinoma patients through specific nomograms, particularly in the era of Intensity-modulated radiotherapy.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Article
Oncology
Michael MacManus, Laura Kirby, Benjamin Blyth, Owen Banks, Olga A. Martin, Miriam M. Yeung, Nikki Plumridge, Mark Shaw, Fiona Hegi-Johnson, Shankar Siva, David Ball, Stephen Q. Wong
Summary: An increase in ctDNA levels was observed after one fraction of fractionated radiotherapy. Further research is needed to determine if this increase in ctDNA levels can serve as a surrogate marker for early treatment response.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Review
Clinical Neurology
James Tanner McMahon, Matthew Studer, Bryan Ulrich, Juan Revuelta M. Barbero, Ivan Pradilla, Maria A. Palacios-Ariza, Gustavo Pradilla
Summary: ctDNA appears to be a highly sensitive and specific noninvasive biomarker among adults with gliomas. The performance of ctDNA is better in cerebrospinal fluid (CSF) compared to plasma, although the difference is not statistically significant. Targeted genetic analysis platforms improve ctDNA detection, particularly in high-grade gliomas.
Article
Oncology
Yosuke Morimoto, Satoru Matsuda, Hirofumi Kawakubo, Kohei Nakamura, Ryota Kobayashi, Kazuhiko Hisaoka, Jun Okui, Masashi Takeuchi, Eriko Aimono, Kazumasa Fukuda, Rieko Nakamura, Hideyuki Saya, Hiroshi Nishihara, Yuko Kitagawa
Summary: Circulating tumor DNA (ctDNA) can be used to assess the treatment response and postoperative recurrence risk in patients with esophageal squamous cell carcinoma (ESCC) who undergo neoadjuvant chemotherapy and esophagectomy. The presence of multiple concordant mutations in ctDNA and primary tumors in pretreatment samples suggests the potential of ctDNA as a biomarker for predicting pathological response and postoperative recurrence in ESCC.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Cell Biology
Tala Tayoun, Marianne Oulhen, Agathe Aberlenc, Francoise Farace, Patrycja Pawlikowska
Summary: CTCs provide a tool for studying tumor heterogeneity and metastatic potential, with recent progress in single-cell analysis shedding light on genomic instability and its impact on tumor evolution and resistant clones emergence. Evaluating CIN and CNA in CTCs reveals their role in metastatic progression and resistance, despite technical obstacles in single CTC analysis, but showing potential predictive value for genotoxic treatment response.
Review
Pathology
Joseph G. Schroers-Martin, Stefan Alig, Andrea Garofalo, Benoit Tessoulin, Takeshi Sugio, Ash A. Alizadeh
Summary: Molecular monitoring plays a crucial role in the surveillance and clinical management of lymphomas, aided by the high concentration of cell-free DNA and circulating tumor DNA, high somatic mutational burden, and presence of recurrently altered regions. This review summarizes the current evidence on molecular subtyping, classification, treatment response evaluation, surveillance of cellular therapies, and emerging clinical trial strategies for lymphomas.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE
(2023)
Meeting Abstract
Hematology
Jan Boegeholz, Stefan K. Alig, Brian Sworder, Joseph Schroers-Martin, Charles Macaulay, Alexander F. M. Craig, Ulrich Duehrsen, Andreas Huettmann, Jason Westin, Hua-Jay J. Cherng, David B. Miklos, Matthew J. Frank, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh
Meeting Abstract
Hematology
Andrea Garofalo, Stefan K. Alig, Joseph Schroers-Martin, Ragini Malika Shyam, Mari Olsen, David M. Kurtz, Cedric Rossi, Andre Schultz, Karan R. Kathuria, Chih Long Liu, Valeria Spina, Jamie E. Flerlage, Sharon M. Castellino, Ranjana H. Advani, Davide Rossi, Ryan C. Lynch, Olivier Casasnovas, Lianna J. Marks, Michael P. Link, Marc Andre, Peter Vandenberghe, Christian Steidl, Maximilian Diehn, Ash A. Alizadeh
Meeting Abstract
Hematology
David M. Kurtz, Gregory J. Hogan, Andre Schultz, Katerina Kopeckova, Christian Kuffer, Derek Blair, Steve Wagner, Sandra Close, Maximilian Diehn, Jacob J. Chabon, Ash A. Alizadeh, Jason Westin
Meeting Abstract
Hematology
Tanaya Shree, Sarah Haebe, Debra K. Czerwinski, Erik Eckhert, Grady Day, Anuja Sathe, Susan M. Grimes, Matthew J. Frank, Lauren S. Maeda, Ash A. Alizadeh, Ranjana H. Advani, Richard Hoppe, Steven R. Long, Brock Martin, Michael G. Ozawa, Michael S. Khodadoust, Hanlee P. Ji, Ronald Levy
Article
Oncology
Brian J. Sworder, David M. Kurtz, Stefan K. Alig, Matthew J. Frank, Navika Shukla, Andrea Garofalo, Charles W. Macaulay, Mohammad Shahrokh Esfahani, Mari N. Olsen, James Hamilton, Hitomi Hosoya, Mark Hamilton, Jay Y. Spiegel, John H. Baird, Takeshi Sugio, Mia Carleton, Alexander F. M. Craig, Sheren F. Younes, Bita Sahaf, Natasha D. Sheybani, Joseph G. Schroers-Martin, Chih Long Liu, Jean S. Oak, Michael C. Jin, Sara Beygi, Andreas Huttmann, Christine Hanoun, Ulrich Duhrsen, Jason R. Westin, Michael S. Khodadoust, Yasodha Natkunam, Robbie G. Majzner, Crystal L. Mackall, Maximilian Diehn, David B. Miklos, Ash A. Alizadeh
Summary: This study investigates the resistance of anti-CD19 chimeric antigen receptor (CAR19) T cells in relapsed/refractory large B-cell lymphoma (r/rLBCL) patients. By analyzing longitudinal samples from two independent cohorts, it identifies multiple gene alterations associated with resistance, such as B cell identity genes (PAX5 and IRF8), immune checkpoint genes (CD274), and genes affecting the tumor microenvironment (TMEM30A). It also reveals that somatic tumor alterations affect CAR19 therapy at various levels, including CAR19 T cell expansion, persistence, and tumor microenvironment. These findings have implications for improving CAR T cells and personalized therapeutic approaches.
Article
Oncology
Jurik A. Mutter, Stefan K. Alig, Mohammad S. Esfahani, Eliza M. Lauer, Jan Mitschke, David M. Kurtz, Julia Kuehn, Sabine Bleul, Mari Olsen, Chih Long Liu, Michael C. C. Jin, Charles W. Macaulay, Nicolas Neidert, Timo Volk, Michel Eisenblaetter, Sebastian Rauer, Dieter H. Heiland, Jurgen Finke, Justus Duyster, Julius Wehrle, Marco Prinz, Gerald Illerhaus, Peter C. Reinacher, Elisabeth Schorb, Maximilian Diehn, Ash A. Alizadeh, Florian Scherer
Summary: We explored the value of circulating tumor DNA (ctDNA) for early outcome prediction, measurable residual disease monitoring, and surgery-free CNSL identification. CtDNA was detectable in 78% of pretreatment plasma and 100% of CSF samples. Presence of ctDNA in pretreatment plasma was associated with shorter progression-free survival and overall survival. Monitoring ctDNA during treatment identified patients with poor prognosis. We developed a machine learning approach for biopsy-free CNSL identification from ctDNA.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
Ryan C. Lynch, Christina Poh, Chaitra S. Ujjani, Edus H. Warren III, Stephen D. Smith, Mazyar Shadman, Karolyn Morris, Sydney Lee, Heather Rasmussen, Susan Ottemiller, Megan Shelby, Sarith Keo, Kaitlin Verni, David M. Kurtz, Ash A. Alizadeh, Jacob J. Chabon, Gregory J. Hogan, Andre Schulz, Ted Gooley, Jenna M. Voutsinas, Ajay K. Gopal
Summary: The POLARIX trial showed the superiority of Pola over vincristine in the RCHOP regimen for large B-cell lymphomas, but its safety in intensified regimens is unknown. This study evaluated the safety and efficacy of Pola-DA-EPCH-R in aggressive large B-cell lymphomas.
Article
Hematology
Hua-Jay J. Cherng, Stefan K. Alig, Yasuhiro Oki, Loretta J. Nastoupil, Luis Fayad, Sattva S. Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F. M. Craig, Charles W. Macaulay, Maria Alma Rodriguez, Hun Ju Lee, Timothy J. McDonnell, Christopher R. Flowers, Francisco Vega, Michael R. Green, Lei Feng, David M. Kurtz, Ash A. Alizadeh, R. Eric Davis, Jason R. Westin
Summary: LO-CHOP treatment shows high efficacy and tolerability in newly diagnosed DLBCL, leading to a high rate of overall and complete response. It is a potentially effective and well-tolerated treatment option.
Article
Hematology
Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian Till, Vikram M. Raghunathan, Stefan Alig, Ash A. Alizadeh, Avanti Gulhane, Delphine L. Chen, Yolanda Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather Rasmussen, Paul Martin, Edmond Marzbani, Jenna Voutsinas, Ajay K. Gopal
Summary: This study investigated the concurrent administration of pembrolizumab with chemotherapy in untreated classic Hodgkin lymphoma, showing promising safety and efficacy. Although some patients experienced adverse events, the overall response rate was 100% with a complete response rate of 90%.
Review
Biochemistry & Molecular Biology
Kyle Swanson, Eric Wu, Angela Zhang, Ash A. Alizadeh, James Zou
Summary: Machine learning is increasingly used in clinical oncology to diagnose cancers, predict patient outcomes, and inform treatment planning. This review focuses on recent applications of machine learning across the clinical oncology workflow, including medical imaging and molecular data obtained from liquid and solid tumor biopsies for cancer diagnosis, prognosis, and treatment design. Key considerations in developing machine learning for the distinct challenges posed by imaging and molecular data are discussed. The review also examines machine learning models approved for cancer-related patient usage by regulatory agencies and discusses approaches to improve the clinical usefulness of machine learning.
Article
Oncology
Joseph G. Schroers-Martin, Joanne Soo, Gabriel Brisou, Florian Scherer, David M. Kurtz, Brian J. Sworder, Michael S. Khodadoust, Michael C. Jin, Agnes Bru, Chih Long Liu, Henning Stehr, Paolo Vineis, Yasodha Natkunam, Lauren R. Teras, Joo Y. Song, Bertrand Nadel, Maximilian Diehn, Sandrine Roulland, Ash A. Alizadeh
Summary: Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals, suggesting additional lesions are required for lymphomagenesis. CREBBP KAT domain mutations were the most commonly observed precursor lesions, distinguishing patients developing FL from healthy adults with or without BCL2 rearrangements. These mutations can be detected years before clinical diagnosis and may help discriminate individuals at risk for lymphoma development.
Article
Hematology
Patricia Johansson, Stefan Alig, Julia Richter, Christine Hanoun, Jan Rekowski, Jan Duerig, Bauke Ylstra, Daphne de Jong, Wolfram Klapper, Ash A. Alizadeh, Ulrich Duehrsen, Andreas Huettmann
Summary: In DLBCL, a positive interim PET scan predicts treatment failure, and combining it with the presence of an IgM gammopathy can improve prediction. The combination of interim PET and IgM gammopathy can dichotomize the population into high-risk and low-risk groups with significantly different outcomes. Only the interim PET result and IgM gammopathy status were significantly associated with outcome, making them important factors in risk-adapted treatment strategies.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Eliza M. Lauer, Ella Riegler, Jurik A. Mutter, Stefan K. Alig, Sabine Bleul, Julia Kuehn, Lavanya Ranganathan, Christian Klingler, Theo Demerath, Urs Wuertemberger, Alexander Rau, Jakob Weiss, Michel Eisenblaetter, Fabian Bamberg, Marco Prinz, Juergen Finke, Justus Duyster, Gerald Illerhaus, Maximilian Diehn, Ash A. Alizadeh, Elisabeth Schorb, Peter C. Reinacher, Florian Scherer
Summary: The study found that the use of semi-automated three-dimensional tumor volume measurements can serve as strong and independent early predictors of clinical outcomes in central nervous system lymphoma (CNSL) patients. These radiologic features can help improve risk stratification and guide future treatment approaches.
Letter
Medicine, General & Internal
Adam C. Palmer, David M. Kurtz, Ash A. Alizadeh
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
